^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    IL-13-targeted CAR-T immunotherapy

    Related drugs:
    Associations

    News

    Trials
    24d
    Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors (clinicaltrials.gov)
    P1, N=72, Active, not recruiting, Seattle Children's Hospital | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EGFR806-specific CAR T-cell therapy • SC-CAR4BRAIN
    3ms
    An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases (clinicaltrials.gov)
    P1, N=20, Recruiting, Shanghai Cell Therapy Group Co.,Ltd
    New P1 trial
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL13 (Interleukin 13) • IL4 (Interleukin 4)
    3ms
    NCI-2014-01488: Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma (clinicaltrials.gov)
    P1, N=65, Active, not recruiting, City of Hope Medical Center | Trial completion date: Jul 2025 --> Jun 2026
    Trial completion date
    |
    IL13RA2 (Interleukin 13 Receptor Subunit Alpha 2)
    |
    MB-101
    6ms
    Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma (clinicaltrials.gov)
    P1, N=10, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting | N=30 --> 10
    Enrollment closed • Enrollment change
    |
    CD123 (Interleukin 3 Receptor Subunit Alpha)
    |
    MB-101
    10ms
    NCI-2014-01488: Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma (clinicaltrials.gov)
    P1, N=65, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2024 --> Jul 2025
    Trial completion date
    |
    IL13RA2 (Interleukin 13 Receptor Subunit Alpha 2)
    |
    MB-101
    12ms
    IL13RA2-integrated genetically engineered mouse model allows for CAR T cells targeting pediatric high-grade gliomas. (PubMed, Res Sq)
    The model proved effective for evaluating IL13RA2-targeted immunotherapies, with a significant response to CAR T-cell treatment that extended survival (46 days vs. 28 days control; p < 0.0001) and achieved 25% long-term survival in mice. This model facilitates the preclinical assessment of IL13RA2-directed therapies and holds potential for clinical application.
    Preclinical • Journal • CAR T-Cell Therapy • IO biomarker
    |
    TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • ITGAM (Integrin, alpha M) • IL13RA2 (Interleukin 13 Receptor Subunit Alpha 2) • PDGFB (Platelet Derived Growth Factor Subunit B) • IL13 (Interleukin 13) • NES (Nestin)
    |
    TP53 expression • IL13RA2 expression
    1year
    Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=18, Recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Oct 2024 --> Oct 2025
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy • Metastases • Immune cell
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600 • CD123 expression
    |
    cyclophosphamide • fludarabine IV • MB-101
    1year
    NCI-2014-01488: Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma (clinicaltrials.gov)
    P1, N=65, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024
    Trial completion date
    |
    IL13RA2 (Interleukin 13 Receptor Subunit Alpha 2)
    |
    CD123 expression
    |
    MB-101
    over1year
    IL-13Rα2/TGF-β bispecific CAR-T cells counter TGF-β-mediated immune suppression and potentiate anti-tumor responses in glioblastoma. (PubMed, Neuro Oncol)
    Our findings demonstrate that by reprogramming tumor-specific T-cell responses to TGF-β, bispecific IL-13Rα2/TGF-β CAR-T cells resist and remodel the immunosuppressive TME to drive potent anti-tumor responses in GBM.
    Journal • CAR T-Cell Therapy
    |
    TGFB1 (Transforming Growth Factor Beta 1) • IL13RA2 (Interleukin 13 Receptor Subunit Alpha 2) • IL13 (Interleukin 13)
    over1year
    Identification and characterisation of novel CAR-T cells to target IL13Rα2 positive human glioma in vitro and in vivo. (PubMed, Clin Transl Med)
    Taken together, we conclude that the novel scFv-IL-13Rα2 CAR-T cell therapy may offer an effective therapeutic option after designing a careful pre-clinical and clinical study.
    Preclinical • Journal • CAR T-Cell Therapy
    |
    IFNG (Interferon, gamma) • IL13RA2 (Interleukin 13 Receptor Subunit Alpha 2) • IL13 (Interleukin 13) • IL1R1 (Interleukin 1 receptor, type I)
    over1year
    Targeting Interleukin-13 Receptor α2 and EphA2 in Aggressive Breast Cancer Subtypes with Special References to Chimeric Antigen Receptor T-Cell Therapy. (PubMed, Int J Mol Sci)
    With an in-depth analysis of current immunotherapeutic strategies, including the limitations of existing treatments and the potential of dual antigen-targeting CAR T-cell therapies, this review aims to summarize potential future novel, more effective therapeutic interventions for BCA. Through a thorough examination of preclinical and clinical studies, it underlines the urgent need for targeted therapies in combating the high mortality rates associated with Her-2-enriched and TNBC subtypes and discusses the potential role of IL-13Rα2 and EphA2 as promising candidates for the development of CAR T-cell therapies.
    Review • Journal • CAR T-Cell Therapy • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • IL13 (Interleukin 13)
    almost2years
    Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results. (PubMed, Nat Med)
    In both dose level 1 (1 ×107 cells; n = 3) and dose level 2 (2.5 × 107 cells; n = 3), administration of CART-EGFR-IL13Rα2 cells was associated with early-onset neurotoxicity, most consistent with immune effector cell-associated neurotoxicity syndrome (ICANS), and managed with high-dose dexamethasone and anakinra (anti-IL1R). An encouraging early efficacy signal was also detected and requires confirmation with additional patients and longer follow-up time. ClinicalTrials.gov identifier: NCT05168423 .
    P1 data • Journal • CAR T-Cell Therapy
    |
    EGFR (Epidermal growth factor receptor) • IL13RA2 (Interleukin 13 Receptor Subunit Alpha 2) • IL13 (Interleukin 13) • IL1R1 (Interleukin 1 receptor, type I)
    |
    Kineret (anakinra)